Showing results (491-500 of 757) with videos related to

Sort By:
Pageof 76
Clinical Kidney Journal|September 9, 2020
Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney diseaseTurgay Saritas, Sebastian Daniel Reinartz, Jennifer Nadal, et al.
Molecular Genetics and Metabolism|November 11, 2018
The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of expertsDominique P Germain, Michael Arad, Alessandro Burlina, et al.
BMC Cancer|March 8, 2024
Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD studyBarbara Kollerits, Simon Gruber, Inga Steinbrenner, et al.
The New England Journal of Medicine|September 18, 2015
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesBernard Zinman, Christoph Wanner, John M Lachin, et al.
European Journal of Heart Failure|June 17, 2022
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-ReducedFaiez Zannad, João Pedro Ferreira, John Gregson, et al.
European Heart Journal|October 12, 2017
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trialDavid Fitchett, Javed Butler, Philippe van de Borne, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 1, 2019
Children of a lesser god: exclusion of chronic kidney disease patients from clinical trialsCarmine Zoccali, Peter J Blankestijn, Annette Bruchfeld, et al.
Kidney International|May 24, 2013
Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and MetabolismT Alp Ikizler, Noel J Cano, Harold Franch, et al.
Circulation|October 23, 2020
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedFaiez Zannad, João Pedro Ferreira, Stuart J Pocock, et al.
European Journal of Heart Failure|December 11, 2019
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trialMichael Böhm, Jonathan Slawik, Martina Brueckmann, et al.
Pageof 76